©2022 Stanford Medicine
Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease
Not Recruiting
Trial ID: NCT00186667
Purpose
Evaluate the clinical activity of sirolimus in combination with cyclosporine and
corticosteroids as first line therapy for the treatment of chronic Graft Versus Host Disease.
Official Title
An Open Label Study of Sirolimus as Primary Therapy for the Treatment of Chronic GVHD Following Allogeneic Bone Marrow Transplant
Stanford Investigator(s)
Laura Johnston
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Eligibility
Inclusion Criteria:- active chronic GvHD
- ANC > 1000/mm^3
- therapeutic cyclosporine Exclusion Criteria:- uncontrolled systemic infection
- elevated serum creatinine
Intervention(s):
procedure: high dose chemotherapy and autologous hematopoietic cell transplant
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
BMT Referrals
6507230822